Answers are grounded in this paper and cite their sources.
Review highlights targeting nitric oxide synthase to reduce metastasis in solid malignancies, suggesting improved efficacy for chemo- and radiotherapies.
Utilizing targeted therapies capable of reducing cancer metastasis, targeting chemoresistant and self-renewing cancer stem cells, and augmenting the efficacy of systemic chemo/radiotherapies is vital to minimize cancer-associated mortality. Targeting nitric oxide synthase (NOS), a protein within the tumor microenvironment, has gained interest as a promising therapeutic strategy to reduce metastatic capacity and augment the efficacy of chemo/radiotherapies in various solid malignancies. Our review highlights the influence of nitric oxide (NO) in tumor progression and cancer metastasis, as well as promising preclinical studies that evaluated NOS inhibitors as anticancer therapies. Lastly, we highlight the prospects and outstanding challenges of using NOS inhibitors in the clinical setting.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: